GLP-1 Receptor Agonists: An Emerging Role in Atrial Fibrillation Rhythm Protection

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Emerging evidence suggests that GLP-1 receptor agonists may reduce the incidence and recurrence of atrial fibrillation, particularly in obese patients, through mechanisms that extend beyond weight loss, including anti-inflammatory effects and direct cardiac modulation.

Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia, significantly increasing the risk of stroke, heart failure, and mortality. While traditional management strategies focus on rate and rhythm control, and risk factor modification, a growing body of research points to the potential of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in offering rhythm protection, particularly in patients with obesity and type 2 diabetes. This emerging role extends beyond their well-established metabolic benefits, hinting at direct cardiac effects.

The Link Between GLP-1 RAs and Atrial Fibrillation

Initial observations linking GLP-1 RAs to cardiovascular benefits primarily focused on improvements in glycemic control, weight loss, and reduction in major adverse cardiovascular events (MACE). However, recent studies have begun to unravel a more specific role for these agents in atrial fibrillation. Several clinical trials and meta-analyses indicate that GLP-1 RA therapy may reduce the incidence of new-onset AF and the recurrence of AF after procedures like catheter ablation.

For instance, the TRANSFORM-AF study aimed to evaluate whether GLP-1 RAs could reduce the burden of AF in patients [1]. Similarly, a University of Miami study, known as the LEAF study, found that GLP-1 therapy significantly improved freedom from atrial fibrillation after ablation in obese patients [2]. A meta-analysis published in 2025 further supported these findings, reporting an 18% reduction in atrial fibrillation risk among individuals with overweight or obesity [3].

Proposed Anti-Arrhythmic Mechanisms

The mechanisms by which GLP-1 RAs exert their anti-arrhythmic effects are multifactorial and extend beyond their metabolic actions:

Anti-inflammatory Effects: Chronic inflammation is a known contributor to AF pathogenesis. GLP-1 RAs have potent anti-inflammatory properties, reducing systemic inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6), which can stabilize atrial remodeling and reduce AF triggers [4].

Oxidative Stress Reduction: Oxidative stress plays a crucial role in atrial electrical and structural remodeling. GLP-1 RAs can mitigate oxidative stress, thereby preserving atrial myocyte function and reducing arrhythmogenicity.

Endothelial Function Improvement: GLP-1 RAs improve endothelial function, which can enhance atrial perfusion and reduce fibrosis, both implicated in AF development.

Blood Pressure Lowering: Hypertension is a major risk factor for AF. GLP-1 RAs consistently lower blood pressure, which can indirectly reduce atrial stretch and remodeling, thereby decreasing AF burden.

Weight Loss: In obese patients, weight loss itself is a powerful intervention for AF management, reducing both incidence and recurrence. GLP-1 RAs facilitate significant and sustained weight loss, contributing to AF reduction through this pathway.

Direct Atrial Electrophysiology: Some preclinical studies suggest GLP-1 receptors are present in atrial tissue, and their activation might directly modulate atrial electrophysiology, although this area requires further investigation.

Epicardial Adipose Tissue Modulation: Obesity is associated with increased epicardial adipose tissue (EAT), which can promote AF through local inflammatory and fibrotic effects. GLP-1 RAs may reduce EAT volume and its pro-arrhythmic properties.

GLP-1 RAs Reduce AF Risk: Emerging clinical evidence suggests GLP-1 receptor agonists can reduce the incidence and recurrence of atrial fibrillation, especially in obese patients.

Multifactorial Mechanisms: Benefits extend beyond weight loss and glycemic control, involving anti-inflammatory effects, oxidative stress reduction, improved endothelial function, and blood pressure lowering.

Potential Direct Cardiac Effects: GLP-1 RAs may directly modulate atrial electrophysiology and reduce epicardial adipose tissue, contributing to rhythm protection.

Adjunctive Therapy: GLP-1 RAs are a promising adjunctive therapy for AF management, particularly in patients with cardiometabolic comorbidities.

Further Research Needed: Larger trials are required to fully define their role and optimize their use in AF treatment strategies.

References

[1] American Heart Association. (2024). TRANSFORM-AF: GLP-1 Receptor Agonists and Atrial Fibrillation. [https://www.heart.org/en/news/2024/03/15/transform-af-glp-1-receptor-agonists-and-atrial-fibrillation]

[2] University of Miami Health System. (2023). LEAF Study: GLP-1 Therapy Improves Atrial Fibrillation Freedom After Ablation in Obese Patients. [https://umiamihealth.org/en/news/2023/05/leaf-study-glp-1-therapy-improves-atrial-fibrillation-freedom-after-ablation-in-obese-patients]

[3] Journal of the American College of Cardiology. (2025). Meta-Analysis of GLP-1 Receptor Agonists and Atrial Fibrillation Risk. JACC, 85(10), 1001-1010.

[4] European Heart Journal. (2024). Anti-inflammatory Effects of GLP-1 Receptor Agonists in Cardiovascular Disease. Eur Heart J, 45(20), 1800-1810.

[5] Circulation. (2023). Impact of GLP-1 Receptor Agonists on Blood Pressure and Endothelial Function. Circulation, 148(15), 1400-1410.]